Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod versus placebo in chronic inflammatory demyelinating polyradiculoneuropathy
NL-OMON41319Phase 2Active, not recruiting
- Sponsor
- Novartis
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic inflammatory demyelinating polyneuropathy (CIDP) comparing Fingolimod with Placebo (2 arms). Started Jun 2013; status: active, not recruiting.
02
Drugs
fingolimod
03
Conditions
chronic inflammatory demyelinating polyneuropathy (CIDP)
Beyond the preview
Go deeper on NL-OMON41319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON41319.